Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental blood cancer drug trial halted early

NCT ID NCT05086315

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tested a new drug called SAR443579 in adults and children with certain blood cancers that had come back or not responded to treatment. The goal was to see if the drug was safe and could shrink or control the cancer. The trial was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia acute myeloid leukemia B-cell acute lymphoblastic leukemia CD4+/CD56+ hematodermic neoplasm myelodysplastic syndrome Myelodysplastic Syndromes Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOCYTIC LEUKAEMIA ACUTE MYELOID LEUKAEMIA REFRACTORY BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASIA MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center-Site Number:8400004

    Boston, Massachusetts, 02215, United States

  • City of Hope-Site Number:8400002

    Duarte, California, 91010, United States

  • Emory University School of Medicine- Grady Campus- Site Number : 8400006

    Atlanta, Georgia, 30303, United States

  • Investigational Site Number : 1560001

    Tianjin, 300020, China

  • Investigational Site Number : 1560003

    Zhengzhou, 450008, China

  • Investigational Site Number : 2500004

    Paris, 75019, France

  • Investigational Site Number : 5280005

    Nijmegen, 6525 GA, Netherlands

  • Investigational Site Number :0360001

    Melbourne, Victoria, 3004, Australia

  • Investigational Site Number :0360002

    Melbourne, Victoria, 3000, Australia

  • Investigational Site Number :2500001

    Paris, 75010, France

  • Investigational Site Number :2500002

    Marseille, 13009, France

  • Investigational Site Number :2500003

    Villejuif, 94800, France

  • Investigational Site Number :5280001

    Rotterdam, 3015 CE, Netherlands

  • Investigational Site Number :5280002

    Amsterdam, 1081 HV, Netherlands

  • Investigational Site Number :5280003

    Groningen, 9713 GZ, Netherlands

  • Investigational Site Number :5280004

    Utrecht, 3584 CS, Netherlands

  • MD Anderson Cancer Center-Site Number:8400001

    Houston, Texas, 77030, United States

  • Montefiore Hutchinson Campus- Site Number : 8400012

    The Bronx, New York, 10461, United States

  • Oregon Health and Science University-Site Number:8400011

    Portland, Oregon, 97239, United States

  • Seattle Children's Hospital- Site Number : 8400014

    Seattle, Washington, 98105, United States

  • The Children's Hospital of Philadelphia- Site Number : 8400013

    Philadelphia, Pennsylvania, 19104, United States

  • The Ohio State University- Site Number : 8400009

    Columbus, Ohio, 43210, United States

  • Weill Cornell Medical College-Site Number:8400003

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.